发布求助
文献互助 智能选刊 最新文献

Medicom Conference Report ESMO 2023最新文献

筛选
英文 中文
First-line and second-line benefit of amivantamab in advanced, EGFR-mutated NSCLC 阿米万他单抗在晚期表皮生长因子受体突变非小细胞肺癌中的一线和二线治疗效果
Medicom Conference Report ESMO 2023 Pub Date : 2023-12-19 DOI: 10.55788/0aa273e7
Marten Dooper
{"title":"First-line and second-line benefit of amivantamab in advanced, EGFR-mutated NSCLC","authors":"Marten Dooper","doi":"10.55788/0aa273e7","DOIUrl":"https://doi.org/10.55788/0aa273e7","url":null,"abstract":"","PeriodicalId":506787,"journal":{"name":"Medicom Conference Report ESMO 2023","volume":"28 22","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139171287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative nivolumab boosts event-free survival in NSCLC nivolumab可提高NSCLC围手术期的无事件生存率
Medicom Conference Report ESMO 2023 Pub Date : 2023-12-19 DOI: 10.55788/9697f0e4
Marten Dooper
{"title":"Perioperative nivolumab boosts event-free survival in NSCLC","authors":"Marten Dooper","doi":"10.55788/9697f0e4","DOIUrl":"https://doi.org/10.55788/9697f0e4","url":null,"abstract":"","PeriodicalId":506787,"journal":{"name":"Medicom Conference Report ESMO 2023","volume":"73 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139171636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FOLFIRINOX equals gemcitabine-based chemoradiotherapy in neoadjuvant setting for pancreatic cancer FOLFIRINOX 与吉西他滨为基础的化放疗在胰腺癌新辅助治疗中的疗效相当
Medicom Conference Report ESMO 2023 Pub Date : 2023-12-19 DOI: 10.55788/7d826196
Marten Dooper
{"title":"FOLFIRINOX equals gemcitabine-based chemoradiotherapy in neoadjuvant setting for pancreatic cancer","authors":"Marten Dooper","doi":"10.55788/7d826196","DOIUrl":"https://doi.org/10.55788/7d826196","url":null,"abstract":"","PeriodicalId":506787,"journal":{"name":"Medicom Conference Report ESMO 2023","volume":"405 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139171710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LuPSMA and enzalutamide: a promising combination LuPSMA和恩扎鲁胺：前景广阔的组合
Medicom Conference Report ESMO 2023 Pub Date : 2023-12-19 DOI: 10.55788/00d6aa8f
Marten Dooper
{"title":"LuPSMA and enzalutamide: a promising combination","authors":"Marten Dooper","doi":"10.55788/00d6aa8f","DOIUrl":"https://doi.org/10.55788/00d6aa8f","url":null,"abstract":"","PeriodicalId":506787,"journal":{"name":"Medicom Conference Report ESMO 2023","volume":"82 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139171502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant immune checkpoint blockade safe and effective in MMRd endometrial cancer 新辅助免疫检查点阻断疗法对MMRd子宫内膜癌安全有效
Medicom Conference Report ESMO 2023 Pub Date : 2023-12-19 DOI: 10.55788/6f6df288
Marten Dooper
{"title":"Neoadjuvant immune checkpoint blockade safe and effective in MMRd endometrial cancer","authors":"Marten Dooper","doi":"10.55788/6f6df288","DOIUrl":"https://doi.org/10.55788/6f6df288","url":null,"abstract":"","PeriodicalId":506787,"journal":{"name":"Medicom Conference Report ESMO 2023","volume":"170 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139172219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selective RET inhibitor selpercatinib doubles progression-free survival in RET-mutated NSCLC 选择性RET抑制剂赛帕替尼可将RET突变NSCLC患者的无进展生存期延长一倍
Medicom Conference Report ESMO 2023 Pub Date : 2023-12-19 DOI: 10.55788/aca9f7bd
Marten Dooper
{"title":"Selective RET inhibitor selpercatinib doubles progression-free survival in RET-mutated NSCLC","authors":"Marten Dooper","doi":"10.55788/aca9f7bd","DOIUrl":"https://doi.org/10.55788/aca9f7bd","url":null,"abstract":"","PeriodicalId":506787,"journal":{"name":"Medicom Conference Report ESMO 2023","volume":"62 18","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139171746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addition of pembrolizumab promising in early-stage high-risk ER+/HER2- breast cancer 早期高危ER+/HER2-乳腺癌患者加用pembrolizumab很有希望
Medicom Conference Report ESMO 2023 Pub Date : 2023-12-18 DOI: 10.55788/01f848ba
Marten Dooper
{"title":"Addition of pembrolizumab promising in early-stage high-risk ER+/HER2- breast cancer","authors":"Marten Dooper","doi":"10.55788/01f848ba","DOIUrl":"https://doi.org/10.55788/01f848ba","url":null,"abstract":"","PeriodicalId":506787,"journal":{"name":"Medicom Conference Report ESMO 2023","volume":"29 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139174117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overall survival in patients with initially unresectable colorectal liver metastases does not depend on choice of induction regimen 最初无法切除的结直肠肝转移患者的总生存率与诱导方案的选择无关
Medicom Conference Report ESMO 2023 Pub Date : 2023-12-18 DOI: 10.55788/17bc9bb5
Marten Dooper
{"title":"Overall survival in patients with initially unresectable colorectal liver metastases does not depend on choice of induction regimen","authors":"Marten Dooper","doi":"10.55788/17bc9bb5","DOIUrl":"https://doi.org/10.55788/17bc9bb5","url":null,"abstract":"","PeriodicalId":506787,"journal":{"name":"Medicom Conference Report ESMO 2023","volume":"135 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139174451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Third-line datopotamab deruxtecan improves progression-free survival in previously treated metastatic HR+/HER2- breast cancer compared with chemotherapy 与化疗相比，三线达托帕单抗德鲁司坦能改善既往接受过治疗的转移性HR+/HER2-乳腺癌患者的无进展生存期
Medicom Conference Report ESMO 2023 Pub Date : 2023-12-18 DOI: 10.55788/a2955654
Marten Dooper
{"title":"Third-line datopotamab deruxtecan improves progression-free survival in previously treated metastatic HR+/HER2- breast cancer compared with chemotherapy","authors":"Marten Dooper","doi":"10.55788/a2955654","DOIUrl":"https://doi.org/10.55788/a2955654","url":null,"abstract":"","PeriodicalId":506787,"journal":{"name":"Medicom Conference Report ESMO 2023","volume":"5 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139174757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benefit of pembrolizumab in TNBC remains after 5 years of follow-up 随访5年后，Pembrolizumab对TNBC的疗效依然存在
Medicom Conference Report ESMO 2023 Pub Date : 2023-12-18 DOI: 10.55788/9d33d125
Marten Dooper
{"title":"Benefit of pembrolizumab in TNBC remains after 5 years of follow-up","authors":"Marten Dooper","doi":"10.55788/9d33d125","DOIUrl":"https://doi.org/10.55788/9d33d125","url":null,"abstract":"","PeriodicalId":506787,"journal":{"name":"Medicom Conference Report ESMO 2023","volume":"122 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139173896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书